Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 4
2009 9
2010 13
2011 15
2012 22
2013 16
2014 26
2015 22
2016 17
2017 9
2018 17
2019 19
2020 23
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

189 results
Results by year
Filters applied: . Clear all
Page 1
Fostamatinib for persistent/chronic adult immune thrombocytopenia.
Newland A, Lee EJ, McDonald V, Bussel JB. Newland A, et al. Immunotherapy. 2018 Jan;10(1):9-25. doi: 10.2217/imt-2017-0097. Epub 2017 Oct 2. Immunotherapy. 2018. PMID: 28967793 Free article. Review.
., IVIg, splenectomy, rituximab, thrombopoietic agents) do not provide optimal management for a substantial number of patients with chronic ITP. Fostamatinib disodium is an orally-bioavailable investigational agent being developed for treatment of primary persistent/chroni …
., IVIg, splenectomy, rituximab, thrombopoietic agents) do not provide optimal management for a substantial number of patients with chronic …
Fostamatinib for the treatment of chronic immune thrombocytopenia.
Connell NT, Berliner N. Connell NT, et al. Blood. 2019 May 9;133(19):2027-2030. doi: 10.1182/blood-2018-11-852491. Epub 2019 Feb 25. Blood. 2019. PMID: 30803989 Review.
Fostamatinib is a spleen tyrosine kinase inhibitor recently approved for the treatment of chronic immune thrombocytopenia (ITP) in patients without adequate response to at least 1 prior line of therapy. This article reviews fostmatinib's mechanism of action and its clinica
Fostamatinib is a spleen tyrosine kinase inhibitor recently approved for the treatment of chronic immune thrombocytopenia (ITP) in pa
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.
Bussel J, Arnold DM, Grossbard E, Mayer J, Treliński J, Homenda W, Hellmann A, Windyga J, Sivcheva L, Khalafallah AA, Zaja F, Cooper N, Markovtsov V, Zayed H, Duliege AM. Bussel J, et al. Am J Hematol. 2018 Jul;93(7):921-930. doi: 10.1002/ajh.25125. Epub 2018 May 15. Am J Hematol. 2018. PMID: 29696684 Free PMC article. Clinical Trial.
Baseline median platelet count was 16 000/muL; median duration of ITP was 8.5 years. Stable responses occurred in 18% of patients on fostamatinib vs. 2% on placebo (P = .0003). Overall responses (defined retrospectively as 1 platelet count 50 000/muL within the first 12 we …
Baseline median platelet count was 16 000/muL; median duration of ITP was 8.5 years. Stable responses occurred in 18% of patients on fost
Fostamatinib: First Global Approval.
Markham A. Markham A. Drugs. 2018 Jun;78(9):959-963. doi: 10.1007/s40265-018-0927-1. Drugs. 2018. PMID: 29869203 Review.
Rigel Pharmaceuticals are developing the spleen tyrosine kinase (SYK) inhibitor fostamatinib (TAVALISSE) as a treatment for immune thrombocytopenia (ITP), autoimmune haemolytic anaemia and IgA nephropathy. ...This article summarizes the milestones in the development of …
Rigel Pharmaceuticals are developing the spleen tyrosine kinase (SYK) inhibitor fostamatinib (TAVALISSE) as a treatment for immune th …
Fostamatinib.
[No authors listed] [No authors listed] 2018 Oct 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012–. PMID: 31643662 Free Books & Documents. Review.
Fostamatinib is an orally available small molecule inhibitor of spleen tyrosine kinase that is used to treat chronic immune thrombocytopenia. Fostamatinib is associated with transient and usually mild elevations in serum aminotransferase levels during therapy but ha
Fostamatinib is an orally available small molecule inhibitor of spleen tyrosine kinase that is used to treat chronic immune thrombocy
Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program.
Bussel JB, Arnold DM, Boxer MA, Cooper N, Mayer J, Zayed H, Tong S, Duliege AM. Bussel JB, et al. Am J Hematol. 2019 May;94(5):546-553. doi: 10.1002/ajh.25444. Epub 2019 Mar 13. Am J Hematol. 2019. PMID: 30784097 Free PMC article. Clinical Trial.
The long-term safety and efficacy of fostamatinib were evaluated in a follow-on, open-label extension (OLE) study. Patients received double-blind fostamatinib in the randomized trials, and responders continued the same dose, 100 to 150 mg BID, in the OLE study. ...
The long-term safety and efficacy of fostamatinib were evaluated in a follow-on, open-label extension (OLE) study. Patients received …
Fostamatinib for the treatment of immune thrombocytopenia in adults.
Moore DC, Gebru T, Muslimani A. Moore DC, et al. Am J Health Syst Pharm. 2019 May 17;76(11):789-794. doi: 10.1093/ajhp/zxz052. Am J Health Syst Pharm. 2019. PMID: 30951590
Fostamatinib is indicated for the treatment of adults with immune thrombocytopenia that has had an insufficient response to a previous treatment. ...Being primarily metabolized through the CYP3A4 pathway, fostamatinib is subject to drug-drug interactions and concomi
Fostamatinib is indicated for the treatment of adults with immune thrombocytopenia that has had an insufficient response to a previou
Fostamatinib (Tavalisse) for ITP.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2019 Feb 25;61(1566):28-30. Med Lett Drugs Ther. 2019. PMID: 30845102 No abstract available.
Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA.
McKeage K, Lyseng-Williamson KA. McKeage K, et al. Drugs Ther Perspect. 2018;34(10):451-456. doi: 10.1007/s40267-018-0551-x. Epub 2018 Aug 29. Drugs Ther Perspect. 2018. PMID: 30459507 Free PMC article.
Fostamatinib has a unique mechanism of action, whereby its active metabolite targets the SYK-mediated pathway of platelet destruction. ...Most patients who respond to fostamatinib maintain platelet counts of > 50 10(9)/L for periods of 12 months. ...
Fostamatinib has a unique mechanism of action, whereby its active metabolite targets the SYK-mediated pathway of platelet destruction
Long-term sustained response to fostamatinib in two patients with chronic refractory immune thrombocytopenia (ITP).
Lee EJ, Izak M, Bussel JB. Lee EJ, et al. Br J Haematol. 2020 Apr;189(2):379-382. doi: 10.1111/bjh.16328. Epub 2020 Jan 3. Br J Haematol. 2020. PMID: 31900937
Phase 3 clinical trials demonstrated an overall response in 43% of patients treated with fostamatinib and use for two years has been reported. Herein, we report two patients with long histories of ITP without lasting responses to numerous first-, second- and third-line the …
Phase 3 clinical trials demonstrated an overall response in 43% of patients treated with fostamatinib and use for two years has been …
189 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page